Bcl-2
下级目录
(3'R,6S,9R)-5,6,7,8,9,10-Hexahydro-5'-(2,2,2-trifluoroethyl)-2-[(1E)-3-[4-(trifluoromethyl)-1-piperidinyl]-1-propen-1-yl]spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazolidine]1',1'-dioxide
目录项下的产品
1257044-40-8 / MFCD357044408
2-((7H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide
2-((7H-吡咯并[2,3-b]吡啶-5-基)氧基)-4-(4-((4'-氯-5,5-二甲基-3,4,5,6-四氢-[1,1'-联苯]-2-基)甲基)哌嗪-1-基)-N-(3-硝基-4-(((四氢-2H-吡喃-4-基)甲基氨基)苯基)磺酰基)苯甲酰胺
623165-93-5 / MFCD23165935
MRK003 is a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. MRK003 treatment induced caspase-dependent apoptosis and inhibited proliferation of MM and NHL cell lines and patient cells. Examination of signaling events after treatment showed time-dependent decrease in levels of the notch intracellular domain, Hes1 and c-Myc. MRK003 downregulated cyclin D1, Bcl-Xl and Xiap levels in NHL cells and p21, Bcl-2 and Bcl-Xl in MM cells. In addition, MRK003 caused an upregulation of pAkt, indicating crosstalk with the PI3K/Akt pathway.
(3'R,6S,9R)-5,6,7,8,9,10-六氢-5'-(2,2,2-三氟乙基)-2-[(1E)-3-[4-(三氟甲基)-1-哌啶基]-1-丙烯-1-基]螺[6,9-亚甲基苯并环辛烯E-11,3'-[1,2,5]噻二唑烷]1',1'-二氧化物
35943-35-2 / MFCD00932413
(2R,3R,4S,5R)-2-(3-Amino-5-Methyl-1,4,5,6,8-Pentaazaacenaphthylen-1(5H)-Yl)-5-(Hydroxymethyl)Tetrahydrofuran-3,4-Diol
(2R,3R,4S,5R)-2-(3-氨基-5-甲基-1,4,5,6,8-五氮杂苊烯-1(5H)-基)-5-(羟甲基)四氢呋喃-3,4-二醇
186348-23-2 / MFCD09837792
Ortataxel, also known as IDN5109, is novel seimsynthetic taxane with potential anticancer activity. Ortataxel is characterized by its high tolerability, antitumor efficacy, ability to overcome multidrug resistance, and oral bioavailabilty. In in vitro experiments, IDN5109 showed antiproliferative effects against HNSCC cell lines. After treatment with IDN5109, Bcl-2 and Bcl-XL were down-regulated, Bax was up-regulated, and caspase-3 was activated. After treatment with IDN5109, concentrations of both VEGF and IL-8 in the culture supernatant of HNSCC cells decreased. In in vivo experiments, the oral administration of IDN5109 showed antitumor effects against HNSCC tumor xenografts. Immunohistochemistry showed that IDN5109 inhibited tumor angiogenesis and induced apoptosis in HNSCC cells, producing a decreased blood vessel density and increased apoptosis index. On the basis of these results, IDN5109 is useful as a chemotherapeutic agent against HNSCC.
923564-51-6 / MFCD12756219
(R)-4-(4-((4’-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro-[1,1’-Biphenyl]-2-Yl)Methyl)Piperazin-1-Yl)-N-((4-((4-Morpholino-1-(Phenylthio)Butan-2-Yl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide
(R)-4-(4-((4’-氯-4,4-二甲基-3,4,5,6-四氢-[1,1’-联苯]-2-基)甲基)哌嗪-1-基)-N-((4-((4-吗啉-1-(苯硫基)丁烷-2-基)氨基)-3-((三氟甲基)磺酰)苯基)磺酰)苯甲酰胺
877877-35-5 / MFCD17010275
TW-37 is a small-molecule inhibitor of Bcl-2 family proteins, inhibited cell growth and induced apoptosis in pancreatic cancer. TW-37 induces cell growth inhibition and S-phase cell cycle arrest, with regulation of several important cell cycle-related genes like p27, p57, E2F-1, cdc25A, CDK4, cyclin A, cyclin D1, and cyclin E. The cell growth inhibition was accompanied by increased apoptosis with concomitant attenuation of Notch-1, Jagged-1, and its downstream genes such as Hes-1 in vitro and in vivo.
N-[4-(2-叔丁基苯磺酰基)苯基]-2,3,4-三羟基-5-(2-异丙基苄基)苯甲酰胺